10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2026)

10x Genomics (TXG) has 9 years of Other Non-Current Liabilities data on file, last reported at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 18.9% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (up 18.9% YoY), and the FY2025 full-year result was $6.5 million, changed N/A from the prior year.
• Other Non-Current Liabilities fell to $6.4 million in Q1 2026, from $6.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $10.1 million in Q3 2023 to a low of $3.0 million in Q4 2022.
• A 5-year average of $6.3 million and a median of $6.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 63.88% in 2022 and soared 77.04% in 2023, its largest moves.
• Tracing TXG's Other Non-Current Liabilities over 5 years: stood at $3.0 million in 2022, then jumped by 43.65% to $4.3 million in 2023, then grew by 15.67% to $4.9 million in 2024, then soared by 30.86% to $6.5 million in 2025, then slipped by 0.82% to $6.4 million in 2026.
• Business Quant data shows TXG's Other Non-Current Liabilities at $6.4 million in Q1 2026, $6.5 million in Q4 2025, and $6.4 million in Q3 2025.